Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Evotec Licenses Compounds To Janssen
by Rick Mullin
July 16, 2012
| A version of this story appeared in
Volume 90, Issue 29
Evotec, a German contract research organization, has licensed to Janssen Pharmaceuticals a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells. The antidiabetes compounds were identified by scientists at Harvard University and analyzed by researchers at CureBeta, an R&D joint venture established last year by Evotec, Harvard, and Howard Hughes Medical Institute to develop disease-state-modifying therapeutic targets. Janssen, a division of Johnson & Johnson, will pay $8 million up front and could make milestone payments of up to $300 million per product.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X